Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Vifor Pharma said to have confirmed the purchase of Sarepta's (SRPT) Priority Review Voucher - Bloomberg
February 25, 2020 12:14 PM ESTVifor Pharma said to have confirmed the purchase of Sarepta's (NASDAQ: SRPT) Priority Review Voucher, as rumored earlier. - Bloomberg
... MoreSarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
February 25, 2020 11:03 AM ESTRBC Capital analyst Brian Abrahams said there are signs that Sarepta Therapeutics (NASDAQ: SRPT) sold its Priority Review Voucher to Vifor Pharma.
"... we note a notice emerging just this morning from FTC providing clearance for an undisclosed transaction between SRPT and Vifor... More
